Wells Fargo analyst Larry Biegelsen raised his price target for Stryker to $228 from $219, while reiterating an Outperform rating on the shares. The analyst notes that Stryker's MAKO TKA surgeon training in his monthly MAKO Surgeon Tracker accelerated sequentially in Q2 to 18.9% from Q1 levels of 5.7%. Overall, MAKO has been a key driver of the company's U.S. knee growth since its full launch in mid-2017, he contends, adding that he continues to believe that there is much runway for growth as MAKO remains vastly underpenetrated both from a system placement and procedure volume standpoint, globally.